Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05180565
Other study ID # SAFE2019
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 18, 2019
Est. completion date March 31, 2022

Study information

Verified date May 2022
Source SafeHeal Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A clinical trial to assess the efficacy, mechanism of action and safety of the Colovac+ Colorectal Anastomosis Protection Device in providing temporary protection of the anastomosis in subjects undergoing lower anterior resection for colorectal cancer


Description:

A primary diverting stoma is widely used by surgeons in order to bypass the low rectal anastomosis and reduce morbidity associated with anastomotic leaks. Typically, a stoma is created for all high-risk patients which means that many patients are exposed to potentially serious complications associated with the stoma itself without any clinical benefit. Colovac+ is a local, temporary, minimally invasive bypass device that provides protection of the anastomosis and safely postpones stoma creation for 10 days after surgery. By postponing stoma creation for 10 days, Colovac is designed to avoid stoma creation in all patients except those patients whose anastomoses have not healed by 10 days after surgery, allowing the others to return to normal activity more quickly and safely.


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date March 31, 2022
Est. primary completion date February 28, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patients (18 years of age or older) - Eligible to undergo open or minimally invasive sphincter-sparing low anterior resection with planned diverting loop ileostomy for malignancy, based on multidisciplinary team recommendations. - Willingness to comply with Clinical Investigation Plan-specific treatment and study visits and to sign a written Informed Consent Form Exclusion Criteria: - Preoperatively : 1. Patient with inflammatory bowel disease 2. Known allergy to nickel or other components of the Colovac+ kit 3. Pregnant or nursing female subject 4. Concomitant major surgical procedure in combination with Colorectal resection (i.e. hepatectomy) 5. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation, impair the ability of the participant to undergo Clinical Investigation Plan described procedures or interfere with the interpretation of study results. including, but not limited to: 1. COVID-19 positive (active infection) based on test within 72 hours prior to surgery 2. Metastatic disease - unless previously treated with chemotherapy and resection, and the benefit of exposure to the Colovac device is greater than the risk 1 3. Immunodeficiency (CD4+ count < 500 CU MM) 4. Systemic steroid therapy within the past 6 months 5. Systemic infection at the time of surgery or requiring systemic antimicrobial therapy up to 1 week before surgery 6. Major surgical or interventional procedures within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study 7. Diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, intraabdominal infection, ischemic bowel, carcinomatosis 8. Fecal incontinence, involvement of sphincter by the neoplastic disease or evidence of extensive local disease in the pelvis seen on pre-operative imaging 9. Severe Malnutrition defined as 10% weight loss within 3 months prior to enrollment. 6. The subject is currently participating in another investigational drug or device study - Intraoperatively : 7. Anastomosis placement at more than 10cm from anal margin 8. Occurrence of any of the following during the colorectal surgery: 1. Blood loss (>750 cc) 2. Blood transfusion 3. Any new sign of ischemia 4. Positive air leak test - requiring re intervention on the anastomosis 5. Inadequate bowel preparation 6. Other intra-operative risks that preclude the subject from undergoing the procedure with the investigational device

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Colovac
A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)

Locations

Country Name City State
Belgium UZA Antwerp
Belgium Centre Hospitalier Universitaire St Pierre Brussels
France CHU Lille Lille
France ICM Montpellier Montpellier
France Hôpital Saint Antoine Paris Paris
France Hôpital Saint Louis Paris
France CHRU Strasbourg Strasbourg

Sponsors (1)

Lead Sponsor Collaborator
SafeHeal Inc

Countries where clinical trial is conducted

Belgium,  France, 

Outcome

Type Measure Description Time frame Safety issue
Primary To measure the incidence of serious adverse events related to using the device The primary endpoint will be a measurement of SAEs probably related or causaly related to the use of the investigational device, to the index surgery in this clinical trial. 3 months
Secondary To measure the number of participants with evidence of absence of feces between the sheath and the colonic wall before device retrieval Rate of patients with evidence of absence of feces between the sheath and the colonic wall before device retrieval at 10 days: 10 days
Secondary To measure the rate of ostomy avoidance To measure the number of participants where ostomy was avoided 3 months
Secondary To evaluate the occurrence of clinical anastomotic leakage 3 months
Secondary To measure on a scale of 1 to 5 rated by the surgeon the ease of device introduction, positioning and endoscopic retrieval Ease of device introduction and positioning will be rated by the surgeon on a scale from 1 to 5 (1 being very easy and 5 being impossible)
Ease of endoscopic retrieval of the device will be rated by the endoscopist on a scale from 1 to 5 (1 being very easy and 5 being impossible)
10 days
Secondary To evaluate the clinically significant migration rate 10 days
Secondary To evaluate the integrity above the anchoring site during the device retrieval using endoscopy. Mucosal appearance above the anchoring site will be evaluated endoscopically during device retrieval and classified as Normal/Inflamed, Bleeding, Ulcerated, Perforated. 10 days
Secondary To evaluate the integrity of the anchoring site during the device retrieval using endoscopy. Mucosal appearance at the anchoring site will be evaluated endoscopically during device retrieval and classified as Normal/Inflamed, Bleeding, Ulcerated, Perforated. 10 days
Secondary To evaluate the integrity of the anastomosis before the device retrieval using fluoroscopy Fluoroscopy with injection of contrast between the colonic wall and the sheath will be performed prior to retrieval of the Colovac+ Device in order to check for anastomotic integrity before device retrieval.
Outcome is measured with presence/absence of any contrast liquid leak through the anastomosis prior to device retrieval.
10 days
Secondary To evaluate the integrity of the anastomosis after the device retrieval using fluoroscopy Fluoroscopy with injection of contrast per rectum will be performed immediately after retrieval of the Colovac+ Device in order to check for anastomotic integrity following device retrieval.
Outcome is measured with presence/absence of any contrast liquid leak through the anastomosis after device retrieval.
10 days
Secondary To measure the average procedure time 1 day
Secondary To measure the patient tolerability of the device using a patient questionnaire Responses to a patient questionnaire on device acceptance, on the device handling and comfort, and on preference compared to an ostomy - utilizing the NIH's (National Institute of Health) PROMIS (Patient-Reported Outcomes Measurement Information System) health measurement questionnaires to assess parameters like pain, bowel incontinence, constipation, diarrhea, or anxiety and social isolation, on a scale from 1 to 10 (1 being absence of difficulty and 10 being severe problems). 10 days
See also
  Status Clinical Trial Phase
Suspended NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Not yet recruiting NCT05775146 - SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases Phase 2
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A